News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,894 Results
Type
Article (43724)
Company Profile (473)
Press Release (694684)
Multimedia
Podcasts (124)
Webinars (20)
Section
Business (209329)
Career Advice (2041)
Deals (36153)
Drug Delivery (120)
Drug Development (83977)
Employer Resources (174)
FDA (16701)
Job Trends (15191)
News (354192)
Policy (33285)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2661)
Accelerated approval (37)
Adcomms (28)
Allergies (148)
Alliances (51111)
ALS (179)
Alzheimer's disease (1738)
Antibody-drug conjugate (ADC) (335)
Approvals (16942)
Artificial intelligence (554)
Autoimmune disease (166)
Automation (42)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (196)
Biotechnology (331)
Bladder cancer (165)
Brain cancer (61)
Breast cancer (660)
Cancer (5004)
Cardiovascular disease (426)
Career advice (1726)
Career pathing (38)
CAR-T (295)
CDC (48)
Celiac Disease (2)
Cell therapy (790)
Cervical cancer (36)
Clinical research (71517)
Collaboration (1822)
Company closure (4)
Compensation (1195)
Complete response letters (67)
COVID-19 (2775)
CRISPR (102)
C-suite (907)
Cystic fibrosis (152)
Data (6405)
Decentralized trials (2)
Denatured (40)
Depression (146)
Diabetes (509)
Diagnostics (6775)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (273)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (247)
Earnings (91551)
Editorial (62)
Employer branding (21)
Employer resources (153)
Events (121176)
Executive appointments (1017)
FDA (19895)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1551)
Gene editing (218)
Generative AI (46)
Gene therapy (651)
GLP-1 (1013)
Government (4768)
Grass and pollen (6)
Guidances (385)
Healthcare (19215)
HIV (64)
Huntington's disease (47)
IgA nephropathy (88)
Immunology and inflammation (280)
Immuno-oncology (66)
Indications (119)
Infectious disease (3057)
Inflammatory bowel disease (205)
Inflation Reduction Act (17)
Influenza (122)
Intellectual property (259)
Interviews (316)
IPO (16933)
IRA (53)
Job creations (3714)
Job search strategy (1440)
JPM (66)
Kidney cancer (16)
Labor market (86)
Layoffs (582)
Leadership (34)
Legal (8028)
Liver cancer (93)
Longevity (15)
Lung cancer (677)
Lymphoma (388)
Machine learning (43)
Management (59)
Manufacturing (829)
MASH (172)
Medical device (13932)
Medtech (13988)
Mergers & acquisitions (20306)
Metabolic disorders (1331)
Multiple sclerosis (169)
NASH (19)
Neurodegenerative disease (347)
Neuropsychiatric disorders (98)
Neuroscience (3052)
Neurotech (1)
NextGen: Class of 2026 (6770)
Non-profit (4586)
Now hiring (68)
Obesity (638)
Opinion (287)
Ovarian cancer (169)
Pain (206)
Pancreatic cancer (237)
Parkinson's disease (300)
Partnered (34)
Patents (512)
Patient recruitment (513)
Peanut (58)
People (60376)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22493)
Phase 2 (31530)
Phase 3 (23308)
Pipeline (5522)
Policy (303)
Postmarket research (2602)
Preclinical (9614)
Press Release (67)
Prostate cancer (249)
Psychedelics (56)
Radiopharmaceuticals (303)
Rare diseases (909)
Real estate (6065)
Recruiting (71)
Regulatory (25083)
Reports (53)
Research institute (2491)
Resumes & cover letters (354)
Rett syndrome (27)
RNA editing (21)
RSV (81)
Schizophrenia (156)
Series A (257)
Series B (203)
Service/supplier (11)
Sickle cell disease (105)
Special edition (27)
Spinal muscular atrophy (162)
Sponsored (43)
Startups (3806)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (85)
The Weekly (82)
Vaccines (1044)
Venture capital (96)
Weight loss (411)
Women's health (96)
Worklife (19)
Date
Last 7 days (586)
Last 30 days (2330)
Last 365 days (30619)
2026 (4117)
2025 (31063)
2024 (36297)
2023 (41014)
2022 (52277)
2021 (56763)
2020 (54921)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (754)
Alabama (90)
Alaska (7)
Arizona (320)
Arkansas (14)
Asia (40724)
Australia (6769)
California (11627)
Canada (3345)
China (1147)
Colorado (490)
Connecticut (504)
Delaware (344)
Europe (89338)
Florida (1722)
Georgia (365)
Hawaii (3)
Idaho (61)
Illinois (897)
India (70)
Indiana (533)
Iowa (24)
Japan (444)
Kansas (131)
Kentucky (42)
Louisiana (27)
Maine (72)
Maryland (1420)
Massachusetts (8445)
Michigan (330)
Minnesota (644)
Mississippi (5)
Missouri (130)
Montana (34)
Nebraska (28)
Nevada (122)
New Hampshire (84)
New Jersey (3090)
New Mexico (31)
New York (3046)
North Carolina (1552)
North Dakota (9)
Northern California (5668)
Ohio (342)
Oklahoma (21)
Oregon (45)
Pennsylvania (2332)
Puerto Rico (24)
Rhode Island (49)
South America (1122)
South Carolina (67)
South Dakota (1)
Southern California (4512)
Tennessee (178)
Texas (1786)
United States (41361)
Utah (346)
Vermont (1)
Virginia (272)
Washington D.C. (82)
Washington State (965)
West Virginia (4)
Wisconsin (117)
Wyoming (2)
738,894 Results for "esperion therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada
May 8, 2025
·
6 min read
Press Releases
Sale of Intellectual Property – Mythic Therapeutics Inc.
December 23, 2025
·
1 min read
Press Releases
Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)
January 13, 2026
·
9 min read
Press Releases
Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand International IP Coverage for OT-101, Strengthening CNS and Neurology Commercialization Pathway
February 12, 2026
·
6 min read
Press Releases
Oncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified Pipeline
February 10, 2026
·
7 min read
Policy
Daiichi Sankyo to Pay Esperion $125M in Settlement of Milestone Payment Lawsuit
Wednesday’s settlement resolves a legal dispute between Daiichi Sankyo Europe and Esperion Therapeutics regarding milestone payments under their cardiovascular drug collaboration.
January 4, 2024
·
2 min read
·
Tyler Patchen
Press Releases
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
January 16, 2026
·
8 min read
FDA
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients.
March 22, 2024
·
10 min read
Press Releases
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 2, 2026
February 3, 2026
·
2 min read
Press Releases
Zevra Therapeutics, Inc. Announces CFO Transition
November 21, 2025
·
3 min read
1 of 73,890
Next
